XML 38 R20.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Collaboration Agreements (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2017
Collaborative Arrangement with Ipsen [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Schedule of Collaborative Revenues Under Collaboration Agreement | During the three months ended March 31, 2017 and 2016, collaboration revenues under the Ipsen Collaboration Agreement were as follows (in thousands):
| Three Months Ended March 31,
| 2017 |  | 2016
Amortization of upfront payments and deferred milestone | $ | 4,305 |  |  | $ | 1,198 |
Royalty revenue | 224 |  |  | — |
Development cost reimbursements | 337 |  |  | — |
Product supply agreement revenue | 991 |  |  | — |
Cost of supplied product | (991 | ) |  | — |
Royalty payable to GlaxoSmithKline on net sales by Ipsen | (336 | ) |  | — |
Collaboration revenues under the Ipsen Collaboration Agreement | $ | 4,530 |  |  | $ | 1,198 |
Collaborative Arrangement with Genentech [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Schedule of Collaborative Revenues Under Collaboration Agreement | During the three months ended March 31, 2017 and 2016, ex-U.S. royalty revenues and U.S. losses under the collaboration agreement with Genentech were as follows (in thousands):
| Three Months Ended March 31,
| 2017 |  | 2016
Royalty revenues on ex-U.S. sales of COTELLIC included in Collaboration revenues | $ | 2,298 |  |  | $ | 130 |
U.S. losses included in Selling, general and administrative expenses | $ | (626 | ) |  | $ | (7,293 | )
Collaborative Arrangement with Takeda [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Schedule of Collaborative Revenues Under Collaboration Agreement | During the three months ended March 31, 2017, collaboration revenues under the Takeda Collaboration Agreement were as follows (in thousands):
| Three Months Ended March 31, 2017
Amortization of upfront payment | $ | 1,887 |
Development cost reimbursements | 795 |
Collaboration revenues under the Takeda Collaboration Agreement | $ | 2,682 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |